OVERVIEW

Clinical Briefings™: Expanding the Armamentarium in Psoriasis Treatment: Where Do Tyrosine Kinase 2 (TYK2) Inhibitors Fit Into the Treatment Landscape? is organized by Physicians' Education Resource, LLC (PER).

Release Date: November 27, 2019
Expiration Date: November 27, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Activity Overview:
Psoriasis is the most common immune-mediated inflammatory disease in the United States, affecting approximately 2% to 3% of the population. No cure exists for this chronic, painful, and disfiguring skin condition with its unpredictable course of symptoms, external triggers, and significant comorbidities that can substantially reduce a patient’s quality of life. In the past decade, significant research has increased the understanding of the pathophysiology of psoriasis, leading to the development of targeted disease-modifying therapies. One of those targets is tyrosine kinase 2 (TYK2), a member of the Janus kinase family. Evidence has demonstrated that TYK2 activity is necessary to signal the interleukin (IL)-12 and IL-23 cytokines, and type I interferons, and that blocking TYK2 activity inhibits the signaling effects of IL-12 and IL-23 to ultimately interrupt cellular processes involved in the formation of psoriatic lesions. Furthermore, capitalizing on the TYK2 activity pathway versus a JAK mechanism may provide novel selective treatment agents for psoriasis and other autoimmune diseases without the hematological adverse effects seen with JAK inhibition.

In this Clinical Briefings™ program, a series of audio interviews with dermatology expert Jashin Wu, MD, will update clinicians on emerging agents for the treatment of psoriasis and provide insights and latest evidence for individualized management of psoriasis.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Review the etiology, pathophysiology, and diagnostic considerations of psoriasis
• Evaluate the latest data on the efficacy, safety, and dosing administration of novel TYK2 inhibitors for patients with psoriasis
• Examine the potential impact of targeted TYK2 inhibitors on treatment of patients with psoriasis
• Additional details will be posted as soon as information is available.

Benefits of Participating
• Update your knowledge of treat-to-target guidelines that may improve patient outcomes and treatment satisfaction
• Learn new strategies to improve patient adherence to treatment
• Build confidence in managing patients with moderate-to-severe psoriasis by incorporating biologic therapies into treatment plans
• Gain awareness of the pathophysiology behind emerging psoriasis treatments and recent data on their efficacy and safety